Form 4: Rigel Pharmaceuticals Director Receives Stock Grant

Director Alison L. Hannah acquired 5,750 shares of Rigel Pharmaceuticals common stock through a restricted stock unit vesting.

Summary

• Director Alison L. Hannah was granted 5,750 shares of common stock.
• The acquisition resulted from the vesting of a restricted stock unit (RSU) award.
• Following this transaction, the director's total beneficial ownership increased to 16,375 shares.
• The shares were acquired at a price of $0 per share as part of a compensation arrangement.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which carries a neutral sentiment.

Positives

• Alignment of director interests with shareholders through equity-based compensation.

Negatives

• None identified.

Risks

• Vesting of the RSU is subject to the director's continuous service on the Board of Directors until the date prior to the next Annual Meeting.

Future Outlook

The restricted stock units are scheduled to fully vest on the date prior to the company's next Annual Meeting, contingent upon the director's continued service.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are standard corporate governance practice in the biotechnology sector to ensure long-term alignment with shareholder value.

Comparison to Industry Standards

• The use of RSU grants for board compensation is consistent with standard practices for mid-cap and small-cap pharmaceutical companies.
• The vesting schedule tied to the annual meeting cycle is a common industry benchmark for director equity awards.

Corporate Governance

Stakeholder Impact

• Minimal impact on shareholders as this is a standard equity-based compensation event.

Next Steps

• Vesting of the RSU award on the date prior to the next Annual Meeting.

Key Dates

Keywords

Rigel Pharmaceuticals, RIGL, Form 4, Insider Trading, Director Compensation, Equity Grant